摘要
目的 进一步证实大黄素在体内对前列腺癌的作用和作用机制。方法 选用PC3-AR荷瘤裸鼠和C3 ( 1) /SV40 转基因小鼠作为动物模型,分别设对照组和治疗组,对照组腹腔注射DMSO ,治疗组腹腔注射大黄素4 0mg/ (kg·d)。每周测动物体重及肿瘤大小。结果 在PC3-AR荷瘤裸鼠中,治疗组小鼠肿瘤体积明显小于对照组(P <0 0 0 1)。在C3 ( 1) /SV40 转基因小鼠中,治疗组小鼠的生存时间明显长于对照组(P <0 0 0 1)。与治疗组相比,对照组小鼠的体重明显降低,皮毛光滑度差,活动能力差。对C3 ( 1) /SV40 转基因小鼠肿瘤进行组织化学染色和Westernbloting分析表明:治疗组小鼠肿瘤表达雄激素受体阳性细胞明显减少(P <0 0 5 ) ;雄激素受体的表达与对照组相比也有明显的降低。此外,对照组小组(1/ 7)与治疗组(7/ 7)相比更具有向周围组织转移和浸润的倾向。以上结果证明了大黄素在体内对前列腺癌的作用机制与体外相同。结论 大黄素不但对前列腺癌的生长有明显的抑制作用,还可抑制前列腺癌的发生。提示大黄素不仅可用于前列腺癌的临床治疗,也可用于前列腺癌的预防。
Objective Try to further demonstrate the function and mechanism of emodin against prostate cancer growth in vivo.Methods The animal models of PC3-AR xenograft nude mice and C 3(1) /SV 40 transgenic mice wert randomnedinto control group(intraperitoneal injection with DMSO)and emodin-trealed group(intraperitoneal injection with emodin.40mg/(kg·d)).The weights of animals and the size of tumor were measured every week.Results In PC-AR xenograft nude mice model,the tumor volume of emodin-treated group is significantly smaller than that of control group(P<0.001).In C 3(1) /SV 40 transgenic mice,the survival of emodin-treated group is much longer than that of control group(P<0.001).In contrast of emodin-treated mice,DMSO-treated control mice significantly lost body weight gain(P<0.05)and emodin-treated mice looked much healthier in the hair grooming and cage activity but the control mice appeared to be in distress patterns.Immunohistochemical staining clearly indicated that the AR expression in PCa tumor tissues from emodin-treated mice were much weaker than those from the control group(P<0.05)and the same results were also obtained by using western blot analysis.In the addition,the emodin-treated mice clearly had a lower incidence of tumor invasion to the periurethral muscle structure(1/7)compared to the control group(7/7).Conclusion Our results suggest that as emodin exerts an inhibitory effect on tumor growth of prostate cancer and on the development of early prostate lesions of prostate carcinogenesis.This compound may be useful for the chemoprevention of prostate cancer and might have utility in prostate cancer therapy.
出处
《癌症进展》
2005年第3期265-269,264,共6页
Oncology Progress
